News and Trends 28 Sep 2018
Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M
Tusk Therapeutics has been acquired by Swiss pharma giant Roche, which aims to develop one of its lead immunological cancer treatments. Roche has given Tusk’s shareholders €70M upfront, with up to an additional €585M planned if Tusk achieves certain milestones. Roche seems particularly interested in one of Tusk’s lead programs, an antibody that reduces the […]